IDEAS home Printed from
   My bibliography  Save this article

Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation


  • Craig Mitton

    (University of British Columbia
    Vancouver Coastal Health Research Institute)

  • Brayan V. Seixas

    (University of British Columbia)

  • Stuart Peacock

    (Simon Fraser University
    BC Cancer)

  • Michael Burgess

    (University of British Columbia
    University of British Columbia)

  • Stirling Bryan

    (University of British Columbia
    Vancouver Coastal Health Research Institute)


Over the last two decades, economic evaluation of health technologies has developed enormously, affirming its importance within the pursuit of efficiency in the management of health care systems. One concern that has been raised with health technology assessment (HTA) has been its operationalization within the realm of decision making. Here, we suggest a mechanism by which HTA can be understood as an input into a broader framework for priority setting and resource allocation. When HTA is seen in this light, topics that at times have had some lack of clarity, such as public engagement and disinvestment, simply become steps in the overall decision-making process.

Suggested Citation

  • Craig Mitton & Brayan V. Seixas & Stuart Peacock & Michael Burgess & Stirling Bryan, 2019. "Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 573-576, October.
  • Handle: RePEc:spr:aphecp:v:17:y:2019:i:5:d:10.1007_s40258-019-00488-1
    DOI: 10.1007/s40258-019-00488-1

    Download full text from publisher

    File URL:
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL:
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    1. Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug, 2015. "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review," PharmacoEconomics, Springer, vol. 33(9), pages 905-924, September.
    2. Craig Mitton & Francois Dionne & Cam Donaldson, 2014. "Managing Healthcare Budgets in Times of Austerity: The Role of Program Budgeting and Marginal Analysis," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 95-102, April.
    3. Baltussen, Rob & Youngkong, Sitapon & Paolucci, Francesco & Niessen, Louis, 2010. "Multi-criteria decision analysis to prioritize health interventions: Capitalizing on first experiences," Health Policy, Elsevier, vol. 96(3), pages 262-264, August.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Ahumada-Canale, Antonio & Jeet, Varinder & Bilgrami, Anam & Seil, Elizabeth & Gu, Yuanyuan & Cutler, Henry, 2023. "Barriers and facilitators to implementing priority setting and resource allocation tools in hospital decisions: A systematic review," Social Science & Medicine, Elsevier, vol. 322(C).
    2. Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & Andr, 2020. "Integrative Review of Managed Entry Agreements: Chances and Limitations," PharmacoEconomics, Springer, vol. 38(11), pages 1165-1185, November.
    3. Baker, Rachel & Mason, Helen & McHugh, Neil & Donaldson, Cam, 2021. "Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices," Social Science & Medicine, Elsevier, vol. 277(C).
    4. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Stanislav Shmelev & Harrison Roger Brook, 2021. "Macro Sustainability across Countries: Key Sector Environmentally Extended Input-Output Analysis," Sustainability, MDPI, vol. 13(21), pages 1-46, October.
    2. Angelo Claudio Palozzo & Andrea Messori, 2016. "Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”," PharmacoEconomics, Springer, vol. 34(4), pages 419-420, April.
    3. Axel C. Mühlbacher & John F. P. Bridges & Susanne Bethge & Ch.-Markos Dintsios & Anja Schwalm & Andreas Gerber-Grote & Matthias Nübling, 2017. "Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(2), pages 155-165, March.
    4. Virginia Wiseman & Craig Mitton & Mary M. Doyle‐Waters & Tom Drake & Lesong Conteh & Anthony T. Newall & Obinna Onwujekwe & Stephen Jan, 2016. "Using Economic Evidence to Set Healthcare Priorities in Low‐Income and Lower‐Middle‐Income Countries: A Systematic Review of Methodological Frameworks," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 140-161, February.
    5. Peter Ghijben & Dennis Petrie & Silva Zavarsek & Gang Chen & Emily Lancsar, 2021. "Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients," PharmacoEconomics, Springer, vol. 39(7), pages 741-756, July.
    6. Sabine Vogler & Peter Schneider & Nina Zimmermann, 2019. "Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing," PharmacoEconomics - Open, Springer, vol. 3(3), pages 303-309, September.
    7. Heenan, Maddie & Jan, Stephen & Ralph, Martyn & Sacks, Gary & Swinburn, Boyd & Shanthosh, Janani, 2023. "Priority setting for non-communicable disease prevention – Co-producing a regulatory agenda informing novel codes of practice in Australia," Social Science & Medicine, Elsevier, vol. 333(C).
    8. Øystein Ariansen Haaland & Frode Lindemark & Kjell Arne Johansson, 2019. "A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-12, October.
    9. Hill, Sarah R. & Vale, Luke & Hunter, David & Henderson, Emily & Oluboyede, Yemi, 2017. "Economic evaluations of alcohol prevention interventions: Is the evidence sufficient? A review of methodological challenges," Health Policy, Elsevier, vol. 121(12), pages 1249-1262.
    10. Mireille M. Goetghebeur & Monika Wagner & Hanane Khoury & Randy J. Levitt & Lonny J. Erickson & Donna Rindress, 2012. "Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA)," Medical Decision Making, , vol. 32(2), pages 376-388, March.
    11. Livio Garattini & Alessandro Curto, 2016. "Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?," PharmacoEconomics, Springer, vol. 34(10), pages 967-969, October.
    12. Angell, Blake & Pares, Jennie & Mooney, Gavin, 2016. "Implementing priority setting frameworks: Insights from leading researchers," Health Policy, Elsevier, vol. 120(12), pages 1389-1394.
    13. MacNeil, Maggie & Koch, Melissa & Kuspinar, Ayse & Juzwishin, Don & Lehoux, Pascale & Stolee, Paul, 2019. "Enabling health technology innovation in Canada: Barriers and facilitators in policy and regulatory processes," Health Policy, Elsevier, vol. 123(2), pages 203-214.
    14. Rotteveel, A.H. & Reckers-Droog, V.T. & Lambooij, M.S. & de Wit, G.A. & van Exel, N.J.A., 2021. "Societal views in the Netherlands on active disinvestment of publicly funded healthcare interventions," Social Science & Medicine, Elsevier, vol. 272(C).
    15. Livia Lovato Pires de Lemos & Augusto Afonso Guerra Júnior & Marisa Santos & Carlos Magliano & Isabela Diniz & Kathiaja Souza & Ramon Gonçalves Pereira & Juliana Alvares & Brian Godman & Marion Bennie, 2018. "The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil," PharmacoEconomics, Springer, vol. 36(2), pages 161-173, February.
    16. Viviane Cássia Pereira & Jorge Otávio Maia Barreto & Francisco Assis da Rocha Neves, 2019. "Health technology reassessment in the Brazilian public health system: Analysis of the current status," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-18, July.
    17. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    18. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    19. Hipgrave, David B. & Alderman, Katarzyna Bolsewicz & Anderson, Ian & Soto, Eliana Jimenez, 2014. "Health sector priority setting at meso-level in lower and middle income countries: Lessons learned, available options and suggested steps," Social Science & Medicine, Elsevier, vol. 102(C), pages 190-200.
    20. Jonathan Karnon & Andrew Partington, 2015. "Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?," PharmacoEconomics, Springer, vol. 33(12), pages 1281-1288, December.

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:17:y:2019:i:5:d:10.1007_s40258-019-00488-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.